Seven Eight Capital’s Regenxbio RGNX Stock Holding History

Seven Eight Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,396	Closed	-$785K	–	684
2018 Q3	$785K	Buy	+10,396	New	+$749K	0.05%	395

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Seven Eight Capital's RGNX Position: Q4 2018 in Review

Seven Eight Capital sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 10,396 shares — an estimated $785K sold.

Seven Eight Capital first reported a position in RGNX in Q3 2018 and held it in 1 quarter. The position peaked at $785K in Q3 2018. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

Seven Eight Capital reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
Seven Eight Capital sold 10,396 Regenxbio shares in Q4 2018, an estimated $785K.
Seven Eight Capital first reported a position in Regenxbio in Q3 2018 and held it in 1 quarter.
Seven Eight Capital's Regenxbio position peaked at $785K in Q3 2018.
183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Seven Eight Capital's 13F filing for Q4 2018, filed 14 Feb 2019.